Beta Drugs Limited (NSE:BETA)

Market Cap	17.11B
Revenue (ttm)	3.35B
Net Income (ttm)	410.00M
Shares Out	10.09M
EPS (ttm)	40.62
PE Ratio	41.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,090
Average Volume	3,439
Open	1,790.20
Previous Close	1,790.20
Day's Range	1,650.00 - 1,790.20
52-Week Range	892.35 - 1,860.00
Beta	0.10
RSI	40.55
Earnings Date	Apr 25, 2025

About Beta Drugs

Beta Drugs Limited develops, manufactures, and sells anti-cancer drugs in India. The company offers oncology products in the areas of breast, lung, head and neck, colorectal, ovarian, gastric, testicular, renal, and prostate cancer, as well as brain tumor, leukemia, lymphoma, myeloma, and supportive cancer; and dermatology products. It also develops active pharmaceutical ingredients. The company exports its products. Beta Drugs Limited was incorporated in 2005 and is based in Panchkula, India.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Employees: 371
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BETA

Financial Performance

In 2023, Beta Drugs's revenue was 2.96 billion, an increase of 30.21% compared to the previous year's 2.27 billion. Earnings were 364.37 million, an increase of 18.62%.